Similar articles

• The pharmacoeconomics of the new antiepileptic drugs.

  Heaney D. Heaney D. Epilepsia. 1999;40 Suppl 8:25-31. doi: 10.1111/j.1528-1157.1999.tb00944.x. Epilepsia. 1999. PMID: 10563592 Review. No abstract available.
• Economic evaluation of epilepsy treatment: a review of the literature.

  Heaney DC, Begley CE. Heaney DC, et al. Epilepsia. 2002;43 Suppl 4:10-6. doi: 10.1046/j.1528-1157.43.s.4.3.x. Epilepsia. 2002. PMID: 12059996 Review.
• Cost-effectiveness of epilepsy therapy: how should treatment effects be measured?

  Langfitt J, Wiebe S. Langfitt J, et al. Epilepsia. 2002;43 Suppl 4:17-24. doi: 10.1046/j.1528-1157.43.s.4.4.x. Epilepsia. 2002. PMID: 12059997
• A comparison of surgical and medical costs for refractory epilepsy.

  Platt M, Sperling MR. Platt M, et al. Epilepsia. 2002;43 Suppl 4:25-31. doi: 10.1046/j.1528-1157.43.s.4.5.x. Epilepsia. 2002. PMID: 12059998 Review. No abstract available.
• Epilepsy at work: evaluating the cost of epilepsy in the workplace.

  Heaney D. Heaney D. Epilepsia. 1999;40 Suppl 8:44-7. doi: 10.1111/j.1528-1157.1999.tb00947.x. Epilepsia. 1999. PMID: 10563595 No abstract available.